Durham, NC (PRWEB) April 22, 2013
Cancer Advances, Inc. (Cancer Advances), a wholly owned, biotechnology portfolio company of Cato BioVentures, announces the issuance of three new patents. Two of the newly released patents cover monoclonal antibodies to progastrin and have been issued in the United States and Australia. The third patent is for a companion diagnostic immunoassay issued in Canada which was previously issued earlier in the year for the United States. Collectively, these patents are additive parts to Cancer Advances’ suite of products that work to inhibit the cancer causing hormone, gastrin 17.
Cancer Advances has developed an intellectual property portfolio that currently holds over 100 United States and worldwide patents related to a lead compound, Polyclonal Antibody Stimulator (PAS) that has been clinically studied in three gastrointestinal cancers. PAS is an active immunotherapeutic that induces antibodies against the hormone, gastrin 17 (G17), and its precursor, (gly)G17, of which there is extensive published evidence for a central role of both of these endogenous compounds in the development and progression of gastrointestinal tumors, as well as other tumors.
The two progastrin patents cover a pharmaceutical composition, comprised of a progastrin-binding molecule that selectively binds to progastrin, a monoclonal antibody to progastrin, and an immunoassy to determine the amount of progastrin in a sample. These patents also cover a method of monitoring treatment of a gastrin-promoted disease or by determining the level of progastrin in a patient.
The third patent, which covers a companion diagnostic immunoassay, is used for the detection and quantitation of gastrin hormones found in a biological fluid sample such as blood. It allows oncologists to identify and target patients who will receive the greatest benefit from treatment with PAS. Slowing tumor growth, improving quality of life, and extending survival for patients suffering from a gastrin hormone-mediated disease are all accomplishments that Cancer Advances has continually strived toward in its research.
“Cancer Advances continues to produce products that progress our efforts in the fight against gastrin-related diseases,” says Lynda Sutton, president of Cancer Advances.
For more information, please contact:
President, Cancer Advances
About Cancer Advances
Cancer Advances is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.
Please visit our product page for more information on what is in development: http://www.canceradvancesinc.com/product.html
# # #
Read the full story at http://www.prweb.com/releases/2013/4/prweb10630275.htm.
Copyright©2012 Vocus, Inc.
All rights reserved